Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 8 sources · 19 days · First seen 21 days ago · Last updated 3 days ago

AbbVie financial performance and strategic transition

Overview

AbbVie is undergoing a strategic shift in its pharmaceutical focus, moving from its legacy product Humira toward new immunology and oncology treatments. In fiscal year 2025, the company reported revenue of $61.2 billion, representing an 8.6% increase from the previous year, with a net income of $4.2 billion. The company also announced a quarterly dividend of $1.73 per share.

Following strong third-quarter results in 2026, AbbVie raised its annual adjusted profit guidance to a range of $13.95 to $13.99 per share. Quarterly revenue reached $17.4 billion, a 10.3% year-over-year increase that exceeded analyst expectations. This growth was largely driven by the immunology franchise, specifically Skyrizi and Rinvoq, which helped offset declining sales of Humira due to the loss of patent exclusivity. Skyrizi generated $5.78 billion in revenue, while Rinvoq brought in $2.71 billion.

Additionally, the neuroscience division saw a 19% revenue increase, reaching $3.39 billion, supported by Botox Therapeutic and Vraylar. To strengthen its long-term pipeline, the company is utilizing acquisitions, including the $10.9 billion purchase of Apogee Therapeutics. The company also announced a 5.2% increase in its quarterly dividend, with higher payments scheduled to begin in February 2027.

Entities

AbbVie Inc. · McKesson & Co. · AbbVie · Cencora · Rinvoq

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] AbbVie reported third-quarter revenue of $17.4 billion. bitfinanzas.com · srnnews.com · stockstory.org
[● 3 SOURCES] The company raised its annual adjusted profit forecast to a range of $13.95 to $13.99 per share. bitfinanzas.com · srnnews.com · stockstory.org
[● 3 SOURCES] AbbVie's adjusted profit per share for the quarter was $3.82. bitfinanzas.com · srnnews.com · stockstory.org
[● 2 SOURCES] Skyrizi recorded quarterly sales of $5.78 billion. bitfinanzas.com · srnnews.com
[● 2 SOURCES] Rinvoq generated $2.71 billion in revenue during the quarter. bitfinanzas.com · srnnews.com
[● 2 SOURCES] AbbVie completed a $10.9 billion acquisition of Apogee Therapeutics in June. srnnews.com · stockstory.org
[○ 1 SOURCE] The neuroscience division revenue increased by 19%. srnnews.com
[○ 1 SOURCE] Humira sales were $683 million for the quarter. bitfinanzas.com

Timeline

3 days ago

[BUSINESS] 8 sources
AbbVie raises profit guidance following strong Q3 results
AbbVie raised its 2026 profit guidance after Q3 revenue hit $17.4 billion, driven by strong sales of Skyrizi and Rinvoq.
21 days ago

[BUSINESS] 4 sources
AbbVie reports $61.2 billion revenue and announces quarterly dividend
AbbVie Inc. reports $61.2 billion in FY2025 revenue amid a transition to new immunology treatments and has announced a quarterly dividend of $1.73 per share.

Sources

bitfinanzas.com · cash.ch · khironclinics.com · rande-academy.cz · srnnews.com · theascent.com · tob.news · unilorin.edu.ng

This summary has been updated 1 time: see revision history